Catalent
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (January 2022) |
![]() | |
Company type | Public company |
---|---|
Industry | Pharmaceuticals |
Predecessor | Cardinal Health PTS |
Founded | 2007 |
Headquarters | Somerset, New Jersey, U.S. |
Number of locations | 49 (2020)[1] |
Key people | Alessandro Maselli (President, CEO & Director), Matti Masanovich (CFO) |
Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 14,000 (2020) |
Website | catalent |
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[3] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[1]
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]
In 2014, Catalent became a public company, listed on the New York Stock Exchange.
History
Before 2007
In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[7]
In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[9]
In 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[6]
From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[6]
Formation of Catalent in 2007
In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[4]
After 2007 and initial public offering-2019
In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[8][11][12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[13]
Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.[14]
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[15]
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[17] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[19]
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[20] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[21] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[22]
In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[24] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[25]
In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[26]
2020-present
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[27] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[28][29]
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[30] AstraZeneca,[31] and Moderna[32] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[33][34] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[35] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility.[36] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[37]
In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.[38]
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.[39]
In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility.[40]
January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).[41][42][43]
Financials
# | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Sales/Revenue | 1.85B | 2.08B | 2.46B | 2.52B | 3.09B | 3.998B | 4.828B |
Total Current Assets | 3.09B | 2.45B | 4.53B | 6.18B | 7.78B | 9.112B | 10.507B |
Net Operating Cash Flow | 155.3M | 299.5M | 374.5M | 247.7M | 440.3M | 0.585B | 0.519B |
References
- ^ a b c "Catalent 2022 Annual Report" (PDF). Catalent Investors. Retrieved 5 June 2023.
- ^ a b c d e "Catalent, Inc. 2020 Annual Report" (PDF). s23.q4cdn.com. 30 June 2021. Retrieved 10 October 2021.
- ^ "Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency". BioSpace. Archived from the original on 1 November 2020. Retrieved 8 November 2020.
- ^ a b "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
- ^ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
- ^ a b c d e f "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015.
- ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
- ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
- ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
- ^ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
- ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
- ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
- ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
- ^ a b "Catalent Issues Initial Public Offering". No. 8. PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
- ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech. 13 November 2014.
- ^ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
- ^ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.
- ^ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. 19 September 2017. Retrieved 21 November 2019.
- ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". Fierce Pharma. 3 July 2018. Retrieved 16 August 2019.
- ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
- ^ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com. 20 March 2019.
- ^ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Retrieved 9 December 2019.
- ^ Hopkins, Kimberly Chin and Jared S. (15 April 2019). "Catalent to Buy Paragon Bioservices for $1.2 Billion". Wall Street Journal. Retrieved 1 November 2019.
- ^ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". Fierce Pharma. 21 May 2019. Retrieved 26 November 2019.
- ^ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Archived from the original on 29 October 2020. Retrieved 23 December 2019.
- ^ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
- ^ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.
- ^ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.
- ^ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.
- ^ "Pfizer to outsource some drug production, focus on coronavirus vaccine". CNBC. 9 May 2020. Retrieved 16 June 2020.
- ^ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine". The New York Times. 15 June 2020. Retrieved 16 June 2020.
- ^ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent". Barrons. Archived from the original on 25 June 2020. Retrieved 7 July 2020.
- ^ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus". The Wall Street Journal. 27 May 2020. Retrieved 16 June 2020.
- ^ "Vaccine makers face biggest medical manufacturing challenge in history". Reuters. 25 June 2020.
- ^ "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland". Baltimore Business Journal. 26 August 2020. Retrieved 24 September 2020.
- ^ "Manufacturer to help develop potential Covid treatment at St. Pete facility". Tampa Bay Business Journal. Retrieved 17 July 2020.
- ^ "Catalent Finalizes RheinCell Therapeutics Acquisition". BioPharm International. 6 August 2021. Archived from the original on 9 August 2021.
- ^ Hopkins, Jared S. (30 August 2021). "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 30 August 2021.
- ^ "Catalent's Momentum Continues with Up to 600 New Jobs Being Added". BioSpace. Retrieved 7 January 2022.
- ^ "Catalent Announces $12 Million Expansion Program at Kansas City Facility". Contract Pharma. Retrieved 2 December 2022.
- ^ Keenan, Joseph (5 January 2023). "Catalent inks deal to manufacture Sarepta's DMD gene therapy". Fierce Pharma. Retrieved 24 January 2023.
- ^ "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal". Endpoints News. Retrieved 24 January 2023.
- ^ "Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate". www.businesswire.com. 5 January 2023. Retrieved 24 January 2023.
External links
- Official website
- Business data for Catalent, Inc.:
- Companies based in Somerset County, New Jersey
- Pharmaceutical companies established in 2007
- Companies listed on the New York Stock Exchange
- Pharmaceutical companies based in New Jersey
- Gene therapy
- Biotechnology companies of the United States
- Multinational companies headquartered in the United States
- Life sciences industry
- Drug discovery companies
- Research and development in the United States
- 2014 initial public offerings